US biopharma Insmed Incorporated has announced that the Phase IIb BiRCh study of brensocatib in chronic rhinosinusitis ...
US biotech VYNE Therapeutics has agreed to merge with privately held Yarrow Bioscience in an all-stock transaction, pivoting ...
US biotech Cytokinetics (Nasdaq: CYTK) has secured the first global approval for its cardiac myosin inhibitor aficamten, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results